New study below [1]. Don't be put off by the title.
When I decided to methodically go through the PubMed PCa literature 12 years ago, I began with vitamins. I can tell you that Vitamin A is the worst starting point. Expecting a single receptor for retinol. I discovered that there was a retinoic acid receptor [RAR] & a retinoid X receptor [RXR] & that each come in three flavors [alpha, beta & gamma], & with up to four splice variants.
PCa causes a change in the expression (occurrence) of these, so it would appear that those that fade from view are the good guys & those whose expression is upregulated must be helpful to the cancer. So I decided that vitamin A supplementation might not be wise.
When retinoic acid receptor–related orphan receptor γ (ROR-γ) cropped up, I'd had enough of the subject, but it might turn out to be important.
It seems that "ROR-γ is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors".
"ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors."
"ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice."
Given that AR is still the main target in CRPC, & that every treatment meets resistance, the idea of an upstream therapy that removes AR from the picture is very attractive.
For a friendlier account of the study & its implications, read:
medicalxpress.com/news/2016...
-Patrick
[1] nature.com/nm/journal/vaop/...
ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer
Junjian Wang,June X Zou,Xiaoqian Xue,Demin Cai,Yan Zhang,Zhijian Duan,Qiuping Xiang,Joy C Yang,Maggie C Louie,Alexander D Borowsky,Allen C Gao,Christopher P Evans,Kit S Lam,Jianzhen Xu,Hsing-Jien Kung,Ronald M Evans,Yong Xu& Hong-Wu Chen
AffiliationsContributionsCorresponding authors
Nature Medicine (2016) doi:10.1038/nm.4070
Received 31 December 2015 Accepted 19 February 2016 Published online 28 March 2016
Abstract
Abstract• Accession codes• References• Author information• Supplementary information
The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the determinants of AR overexpression in CRPC are poorly defined. Here we show that retinoic acid receptor–related orphan receptor γ (ROR-γ) is overexpressed and amplified in metastatic CRPC tumors, and that ROR-γ drives AR expression in the tumors. ROR-γ recruits nuclear receptor coactivator 1 and 3 (NCOA1 and NCOA3, also known as SRC-1 and SRC-3) to an AR–ROR response element (RORE) to stimulate AR gene transcription. ROR-γ antagonists suppress the expression of both AR and its variant AR-V7 in prostate cancer (PCa) cell lines and tumors. ROR-γ antagonists also markedly diminish genome-wide AR binding, H3K27ac abundance and expression of the AR target gene network. Finally, ROR-γ antagonists suppressed tumor growth in multiple AR-expressing, but not AR-negative, xenograft PCa models, and they effectively sensitized CRPC tumors to enzalutamide, without overt toxicity, in mice. Taken together, these results establish ROR-γ as a key player in CRPC by acting upstream of AR and as a potential therapeutic target for advanced PCa.